Nebenwirkungen · Peyona (previously Nymusa)
Peyona 20 mg/mL solution for infusion and oral solution · Abschnitt 4.8 · PDF-Seite 8
HOS-121306 · Präparat HOS-095319
In a post-authorisation safety study on 506 preterm infants treated with Peyona, safety data have been collected in 31 very premature infants with renal/hepatic impairment. Adverse reactions appeared to be more frequent in this subgroup with organ impairment than in other observed infants without organ impairment. Cardiac disorders (tachycardia, including one single case of arrhythmia) were mostly reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-09-18T02:09:00Z · SHA-256 538bfaa1bbc4434dad321d044190ff4102a2e9d6bf1a8fbce0d4ca21d26015c6 · Passage f0ef8975541a68d554c721e8b88cc86922e9a351acedaaf5b07b786eac1d495d · Zeichen 4820–5230 im Abschnitt